IBC Life Sciences, Courtyard Boston Tremont Hotel, Boston, MA
November 12-13, 2007
The 5th Annual International Anti-angiogenesis Conference is aimed to not just update attendees to new drugs but to better describe what makes an efficacious anti-angiogenic drug, how anti-angiogenic drugs fit into the realm of anti-vascular modalities, understanding why and what it takes to improve anti-angiogenic drug activity through combination strategies and appropriate drug delivery, and to learn how to follow activity of anti-angiogenic drugs through measurement and validity of biomarkers. Anti-angiogenic drugs, via their novel mechanisms, offer an opportunity to be used in combination with conventional drugs without significant toxicity. Hence understanding how to work with this new class drugs will enable clinicians and drug developers to better serve the public to help to increase not just the life but the quality of life of the cancer patient. Drug companies, academic groups and contract research industries will benefit from this conference by meeting key industries and opinion leaders in an opportune environment for networking, establishing meaningful relationships and learning from the presenters in a workable attendee group number. For more information and to register, visit http://www.ibclifesciences.com/antiangio.
|
|